Clinical management of cutaneous toxicity of anti-EGFR agents

Marcello Monti, S. Motta

Research output: Contribution to journalArticlepeer-review


Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology. Dermatological adverse reactions, mainly folliculocentric, have been widely reported in the literature. However, the mechanism of these reactions is not well defined and their management is still a matter of debate. In this paper keratinocyte differentiation, activation and pathways regulating gene expression are reviewed in order to improve the understanding of adverse skin reactions and obtain success in their management. The authors had the opportunity to treat skin reactions induced by cetuximab in a cohort of patients affected by metastatic colorectal carcinoma. The aims of this clinical approach were to control the signs and symptoms of skin toxicity in order to avoid delay in cancer therapy and to use nondrug agents for the treatment of drug-induced skin reactions.

Original languageEnglish
JournalInternational Journal of Biological Markers
Issue number1 SUPPL. 4
Publication statusPublished - Jan 2007


  • Anti-EGFR skin toxicity
  • Natural products
  • Skin inflammation

ASJC Scopus subject areas

  • Immunology
  • Biochemistry


Dive into the research topics of 'Clinical management of cutaneous toxicity of anti-EGFR agents'. Together they form a unique fingerprint.

Cite this